Sarclisa (isatuximab-irfc) Escena in combination with standard-of-care regimens received clearance for the treatment of patients with multiple myeloma (MM) across all existing indications of the Sarclisa intravenous (IV) formulation. Approval makes it the first anticancer treatment administered through an on-body injector and manual subcutaneous administration.

Earlier this year, Sanofi invested $30 million in Enable Injections as the companies conducted a study to accelerate Sarclisa approval. Now, they can offer the Sarclisa-delivering device — branded as CirCLIQ — in the U.S.